Cargando…
Management strategy for hematological malignancy patients with acute respiratory failure
Acute respiratory failure (ARF) is still the major cause of intensive care unit (ICU) admission for hematological malignancy (HM) patients although the advance in hematology and supportive care has greatly improved the prognosis. Clinicians have to make decisions whether the HM patients with ARF sho...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447613/ https://www.ncbi.nlm.nih.gov/pubmed/34535193 http://dx.doi.org/10.1186/s40001-021-00579-7 |
_version_ | 1784569053902274560 |
---|---|
author | Jiang, Li Wan, Qunfang Ma, Hongbing |
author_facet | Jiang, Li Wan, Qunfang Ma, Hongbing |
author_sort | Jiang, Li |
collection | PubMed |
description | Acute respiratory failure (ARF) is still the major cause of intensive care unit (ICU) admission for hematological malignancy (HM) patients although the advance in hematology and supportive care has greatly improved the prognosis. Clinicians have to make decisions whether the HM patients with ARF should be sent to ICU and which ventilation support should be administered. Based on the reported investigations related to management of HM patients with ARF, we propose a selection procedure to manage this population and recommend hematological ICU as the optimal setting to recuse these patients, where hematologists and intensivists can collaborate closely and improve the outcomes. Moreover, noninvasive ventilation (NIV) still has its own place for selected HM patients with ARF who have mild hypoxemia and reversible causes. It is also crucial to monitor the efficacy of NIV closely and switch to invasive mechanical ventilation at appropriate timing when NIV shows no apparent improvement. Otherwise, early IMV should be initiated to HM with ARF who have moderate and severe hypoxemia, adult respiratory distress syndrome, multiple organ dysfunction, and unstable hemodynamic. More studies are needed to elucidate the predictors of ICU mortality and ventilatory mode for HM patients with ARF. |
format | Online Article Text |
id | pubmed-8447613 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-84476132021-09-17 Management strategy for hematological malignancy patients with acute respiratory failure Jiang, Li Wan, Qunfang Ma, Hongbing Eur J Med Res Review Acute respiratory failure (ARF) is still the major cause of intensive care unit (ICU) admission for hematological malignancy (HM) patients although the advance in hematology and supportive care has greatly improved the prognosis. Clinicians have to make decisions whether the HM patients with ARF should be sent to ICU and which ventilation support should be administered. Based on the reported investigations related to management of HM patients with ARF, we propose a selection procedure to manage this population and recommend hematological ICU as the optimal setting to recuse these patients, where hematologists and intensivists can collaborate closely and improve the outcomes. Moreover, noninvasive ventilation (NIV) still has its own place for selected HM patients with ARF who have mild hypoxemia and reversible causes. It is also crucial to monitor the efficacy of NIV closely and switch to invasive mechanical ventilation at appropriate timing when NIV shows no apparent improvement. Otherwise, early IMV should be initiated to HM with ARF who have moderate and severe hypoxemia, adult respiratory distress syndrome, multiple organ dysfunction, and unstable hemodynamic. More studies are needed to elucidate the predictors of ICU mortality and ventilatory mode for HM patients with ARF. BioMed Central 2021-09-17 /pmc/articles/PMC8447613/ /pubmed/34535193 http://dx.doi.org/10.1186/s40001-021-00579-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Jiang, Li Wan, Qunfang Ma, Hongbing Management strategy for hematological malignancy patients with acute respiratory failure |
title | Management strategy for hematological malignancy patients with acute respiratory failure |
title_full | Management strategy for hematological malignancy patients with acute respiratory failure |
title_fullStr | Management strategy for hematological malignancy patients with acute respiratory failure |
title_full_unstemmed | Management strategy for hematological malignancy patients with acute respiratory failure |
title_short | Management strategy for hematological malignancy patients with acute respiratory failure |
title_sort | management strategy for hematological malignancy patients with acute respiratory failure |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447613/ https://www.ncbi.nlm.nih.gov/pubmed/34535193 http://dx.doi.org/10.1186/s40001-021-00579-7 |
work_keys_str_mv | AT jiangli managementstrategyforhematologicalmalignancypatientswithacuterespiratoryfailure AT wanqunfang managementstrategyforhematologicalmalignancypatientswithacuterespiratoryfailure AT mahongbing managementstrategyforhematologicalmalignancypatientswithacuterespiratoryfailure |